using computational algorithms to predict the response of mds patients to hypomethylating agents
Published 7 years ago • 110 plays • Length 5:47Download video MP4
Download video MP3
Similar videos
-
1:41
using cytogenetics to improve the diagnosis and prognosis of mds & to predict response to treatment
-
3:21
mode of action of hypomethylating agents for mds
-
3:22
performance of the aipss-mds ml model in predicting os & leukemic transformation in cmml
-
2:33
what can artificial intelligence bring to the diagnosis and management of mds?
-
1:32
the importance of cytogenetics and molecular profiling for accurate aml/mds diagnosis
-
3:43
genomic profiling to predict prognosis for patients with hr-smm
-
3:16
developing patient-specific mrd markers for predicting and preventing mds relapse post-sct
-
33:48
لقاء #طويق_talk الأسبوعي | مستقبل الذكاء الاصطناعي واستعماله في الطب والإنسان
-
9:16
protrombin time (pt) & activated partial tromboplastin time (aptt)|coagulation analyzer|wila djami
-
2:31
emerging treatment options for patients with esa-refractory mds: luspatercept & imetelstat
-
3:32
mds: managing hma failure
-
1:17
using an ai model to quantify under-utilization of allosct for aml in the uk
-
0:48
an introduction to the maxilus study: the optimal dose of luspatercept in lr-mds
-
2:16
phase i study of donor-derived γδ t cells as relapse prophylaxis post haplo/cy
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
1:13
the unmet needs and future of cmml treatment
-
1:32
development of a universal point-of-care coagulometer to resolve the unmet needs in anticoagulation
-
2:14
trial updates for luspatercept in lr-mds: commands, medalist and elements-mds
-
0:59
hdxsim: a clinical decision support tool for model-informed precision dosing of hydroxyurea in scd
-
1:31
pembrolizumab plus avd in chl: long-term follow-up of a phase ii study
-
3:51
venetoclax plus azacitidine in treatment-naïve and r/r mds